Covalon Technologies Ltd. (OTCMKTS:CVALF) Short Interest Update

Covalon Technologies Ltd. (OTCMKTS:CVALF) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 9,400 shares, a growth of 193.8% from the February 13th total of 3,200 shares. Based on an average trading volume of 41,600 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the stock are short sold.

Covalon Technologies Price Performance

Shares of CVALF stock traded down $0.02 on Friday, hitting $1.56. 7,900 shares of the company’s stock were exchanged, compared to its average volume of 22,994. Covalon Technologies has a 12 month low of $0.74 and a 12 month high of $3.08. The company has a 50 day moving average of $2.08 and a 200 day moving average of $2.31. The stock has a market cap of $42.77 million, a P/E ratio of 22.29 and a beta of -0.40.

Covalon Technologies (OTCMKTS:CVALF) last released its quarterly earnings data on Friday, February 21st. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.06. The company had revenue of $5.84 million during the quarter, compared to the consensus estimate of $6.37 million. Covalon Technologies had a return on equity of 12.33% and a net margin of 8.58%.

Covalon Technologies Company Profile

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.